It has been reported that TRPV2 is activated by the lysophospholipids, lysophosphatidylcholine and lysophosphatidylinositol, and TRPV2-knockdown in the prostate cancer cell line PC3 decreases lysophospholipid-induced migration (Monet et al., 2009). This evidence concerns the gene TRPV2 and prostate carcinoma.